SCHEMBL4932705

SCHEMBL4932705

Cn1nc(C2CCN(C(=O)OC(C)(C)C)CC2)ccc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
MAPT P10636 1/20 0.51
THRB P10828 1/20 0.51
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTT P42858 2/20 0.47
GPR119 Q8TDV5 4/20 0.46
TRPV3 Q8NET8 1/20 0.46
MEN1 O00255 2/20 0.46
CRHBP P24387 2/20 0.46
KMT2A Q03164 2/20 0.46
CRHR2 Q13324 2/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPN6 P29350 1/20 0.45
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25731609 0.82 GPR119 (0.50) KDM4EMAPTTHRBHTTGPR119
SCHEMBL20564764 0.80 KDM4E (0.48) KDM4EMAPTTHRBHTTGPR119
SCHEMBL29946091 0.80 KDM4E (0.50) KDM4EMAPTTHRBALDH1A1HPGD
SCHEMBL1373313 0.78 HRH3 (0.64) KDM4EALDH1A1HPGDHTTGPR119
SCHEMBL15188271 0.78 KDM4E (0.48) KDM4EMAPTTHRBALDH1A1HPGD
SCHEMBL31639493 0.77 THRB (0.50) KDM4EMAPTTHRBHPGDNPSR1
SCHEMBL25230307 0.76 NAMPT (0.54) KDM4EMAPTTHRBALDH1A1HPGD
SCHEMBL15174527 0.76 TRPC6 (0.58) KDM4EMAPTTHRBHTTGPR119
SCHEMBL31639582 0.76 HTT (0.53) KDM4EMAPTTHRBALDH1A1HPGD
SCHEMBL25169929 0.76 GPR119 (0.50) KDM4EMAPTTHRBHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214495-A1 Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa ASTRAZENECA AB (SE) 2008-09-04 US disclosed
WO-2007008143-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA ASTRAZENECA AB (SE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214495-A1 Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa F10, F12, F11 KDM4E 2392/4885MAPT 4885/4885THRB 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.